子宫肌瘤与骨盆腔特征是否与泌尿及盆腔症状严重程度相关?
回顾性分析338例子宫肌瘤门诊女性,使用盆腔磁共振成像、盆腔困扰量表(0-300分)和子宫肌瘤症状量表(1-100分)评估症状,多因素线性回归分析显示盆腔困扰量表评分升高与体重指数、非商业保险、产次及失禁手术史相关,肌瘤大小和位置与盆腔底症状严重程度无关,子宫肌瘤症状评分升高与黏膜下优势肌瘤、体重指数、贫血史及激素治疗史相关。
要点
- 肌瘤大小和位置与盆腔底症状严重程度无关。
- 盆腔底症状严重程度与体重指数、产次、失禁手术史相关。
- 肌瘤症状严重程度与黏膜下优势肌瘤和激素治疗史相关。
核心结论
- 在该寻求肌瘤治疗的女性队列中,肌瘤或子宫的大小和位置与盆腔底症状严重程度无关,这与常见观念相反。
- 出血症状严重程度与黏膜下优势肌瘤和既往激素治疗相关。
研究设计与样本
- 回顾性综述(2013-2017年)纳入多学科肌瘤门诊338名女性,均接受盆腔磁共振成像、盆腔困扰量表(0-300分)和子宫肌瘤症状量表(1-100分)评估。
主要发现
- 338名女性盆腔困扰量表中位数为72.7(四分位距41-112.3)。
- 盆腔困扰量表评分升高与体重指数较高(P<.001)、非商业保险(P<.001)、产次增加(P=.001)和失禁手术史(P=.003)相关。
- 子宫体积、优势肌瘤体积、尺寸和位置、肌瘤相对于骨盆腔结构的位置与盆腔底症状严重程度比较未达显著性。
- 子宫肌瘤症状量表平均分为52.0(标准差23.5)。
- 子宫肌瘤症状量表评分升高与黏膜下优势肌瘤(P=.011)、体重指数(P<.0016)、贫血临床史(P<.001)或任何针对肌瘤的激素治疗(P=.009)相关。
临床怎么用
- 作者建议在评估子宫肌瘤女性的盆腔底症状时,应仔细关注体重指数和病史等临床因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Urinary and pelvic floor symptoms often are attributed to size and location of uterine fibroid tumors. However, direct supporting evidence that links increased size to worsening symptoms is scant and limited to ultrasound evaluation of fibroid tumors. Because management of fibroid tumors is targeted towards symptomatic relief, the identification of fibroid and pelvic characteristics that are associated with worse symptoms is vital to the optimization of therapies and prevention needless interventions. OBJECTIVE: We examined the correlation between urinary, pelvic floor and fibroid symptoms, and fibroid size and location using precise uterine fibroid and bony pelvis characteristics that were obtained from magnetic resonance imaging. STUDY DESIGN: A retrospective review (2013-2017) of a multidisciplinary fibroid clinic identified 338 women who had been examined via pelvic magnetic resonance imaging, Pelvic Floor Distress Inventory questionnaire (score 0-300), and a Uterine Fibroid Symptoms questionnaire (score 1-100). Multiple linear regression analysis was used to assess the influence of clinical factors and magnetic resonance imaging findings on scaled Pelvic Floor Distress Inventory and Uterine Fibroid Symptoms scores. Data were analyzed with statistical software. RESULTS: Our cohort of 338 women had a median Pelvic Floor Distress Inventory of 72.7 (interquartile range, 41-112.3). Increased Pelvic Floor Distress Inventory score was associated with clinical factors of higher body mass index (P<.001), noncommercial insurance (P<.001), increased parity (P=.001), and a history of incontinence surgery (P=.003). Uterine volume, dominant fibroid volume, dimension and location, and fibroid tumor location relative to the bony pelvis structure did not reach significance when compared with pelvic floor symptom severity. The mean Uterine Fibroid Symptoms score was 52.0 (standard deviation, 23.5). An increased Uterine Fibroid Symptoms score was associated with dominant submucosal fibroid tumors (P=.011), body mass index (P<.0016), and a clinical history of anemia (P<.001) or any hormonal treatment for fibroid tumors (P=.009). CONCLUSION: Contrary to common belief, in this cohort of women who sought fibroid care, size and position of fibroid tumors or uterus were not associated with pelvic floor symptom severity. Whereas, bleeding symptom severity was associated with dominant submucosal fibroid tumor and previous hormonal treatment. Careful attention to clinical factors such as body mass index and medical history is recommended when pelvic floor symptoms are evaluated in women with uterine fibroid tumors.
引用
- Shaffer RK, Dobberfuhl AD, Vu KN, et al. Are fibroid and bony pelvis characteristics associated with urinary and pelvic symptom severity? Am J Obstet Gynecol. 2019. PMID: 30711512. doi:10.1016/j.ajog.2019.01.230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。